IPP Bureau
Centre deploys high-level team to Kerala to investigate Avian Influenza Outbreak
By IPP Bureau - October 28, 2022
The team will also assist the state health departments in terms of public health measures, management guidelines and protocols to manage the increasing cases of Avian Influenza
Vimta Labs posts consolidated PAT of Rs. 13.21 crores in Q2FY23
By IPP Bureau - October 28, 2022
The company has posted net profit of Rs. 13.21 crores for the period ended September 30, 2022
ProBioGen co-develops new Freedom ExpiCHO-S cell line development kit
By IPP Bureau - October 28, 2022
It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors or prior experience in the field.
Ardigen supports JUMP-CP Consortium scaling up image-based drug discovery with the world’s largest public Cell Painting dataset
By IPP Bureau - October 28, 2022
The JUMP-CP Consortium’s aim is to validate and scale up image-based drug discovery strategies by creating the world’s largest public cell imaging data set
Gland Pharma’s Q2 FY23 revenue stood at Rs. 1,044.4 Cr
By IPP Bureau - October 27, 2022
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Dabur India posts consolidated Q2 FY2023 PAT at Rs. 490.06 Cr
By IPP Bureau - October 27, 2022
The company has reported total income of Rs. 3109.77 crores during the period ended September 30, 2022
Zydus gets USFDA’s approval for Ketorolac Tromethamine Tablets
By IPP Bureau - October 27, 2022
Ketorolac Tromethamine Tablets are indicated to relieve moderately severe pain, usually after surgery.
USFDA Issues a CRL for the Biologics License Application for Insulin Aspart
By IPP Bureau - October 27, 2022
The CRL did not identify any outstanding scientific issues with the product.
Camizestrant significantly improved PFS vs. Faslodex in SERENA-2 Phase II trial
By IPP Bureau - October 27, 2022
Results reinforce commitment to next-generation oral SERD development programme
Robert M. Davis is the new Chairman of Merck
By IPP Bureau - October 27, 2022
Frazier led the company for 10 years as President and Chief Executive Officer, from 2011 through 2021.
ERES IV acquires a majority stake in Oncodesign Services
By IPP Bureau - October 27, 2022
Oncodesign Services (ODS ), with 600 clients in 33 countries and 227 employees worldwide, provides services from target identification to hit-to-lead and lead optimization through to IND filing.
Laurus Labs planning Rs. 2,000 Cr Capex
By IPP Bureau - October 27, 2022
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
CEPI and SK bioscience partner to advance mRNA vaccine technology
By IPP Bureau - October 26, 2022
CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus
Healthcare firms discover ways to use VR to treat neurological diseases, says GlobalData
By IPP Bureau - October 26, 2022
The global VR market to grow at a compound annual growth rate of 13% from $7 billion in 2018 to $28 billion in 2030.
Quizartinib granted priority review in the U.S.
By IPP Bureau - October 26, 2022
Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone
